Misoprostol Dosage in the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Gastric and Duodenal Ulcers: A Comparison of Three Regimens

Raskin, Jeffrey B.; White, Richard; Jackson, Joseph E.; Weaver, Arthur L.; Tindall, Elizabeth A.; Lies, Richard B.; Stanton, David A.

doi:10.7326/0003-4819-123-5-199509010-00004

Cited by 162 publications

(75 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Numerous RCTs have been carried out, both in normal volunteers and in patients with arthritic disorders, to evaluate the efficacy of coadministration of various agents for the prevention of both NSAID-related, nonulcer gastropathy and GU and DU (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). Generally, these have shown that concomitant administration of the prostaglandin E1 analog misoprostol along with various NSAIDs can prevent both GU and DU (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23); that the proton pump inhibitor (PPI) (24 -26) omeprazole reduces GU and prevents DU; and that H2 receptor antagonists are effective in preventing DU but not GU (27,28).…”

Section: Concurrent Use Of Anticoagulantsmentioning

confidence: 99%

A guideline for the treatment and prevention of nsaid-induced ulcers

Lanza

1998

The American Journal of Gastroenterology

View full text Add to dashboard Cite

Section: Concurrent Use Of Anticoagulantsmentioning

confidence: 99%

A guideline for the treatment and prevention of nsaid-induced ulcers

Lanza

1998

The American Journal of Gastroenterology

View full text Add to dashboard Cite

“…64 The method of randomisation was reasonably well described in only two studies 43,64 and incompletely 64 the rest were all 'unclear'.…”

Section: Study Qualitymentioning

confidence: 99%

“…Extra outcome data were provided for only eight of these studies. [37][38][39][40][41][42][43][44] Five offered data on outcomes not previously recorded for that study, five offered information that no events had occurred in some outcomes and four offered data differing from those already collected from the study publication(s). Replies about the same eight studies and one further study 45 provided extra information on study quality (method of randomisation, allocation concealment, etc.…”

Section: Contact With Trialistsmentioning

confidence: 99%

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

Brown¹,

Hooper²,

Elliott³

et al. 2006

Health Technol Assess

137

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE and Science Citation Index Expanded (SciSearch ® ) and Current Contents® /Clinical Medicine. NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of car...

show abstract

“…As pharmaceutical adjuvants to this program, TTM 275,277 and high-dose aspirin, a salicylate salt, or salsalate (∼4.5-6 g daily in multiple divided doses, along with misoprostol, 200 mg twice daily or 3 times daily for GI protection if aspirin is used 328 ) are recommended, under careful physician supervision. Lowdose aspirin, for patients not using high-dose aspirin, can be recommended as an antithrombotic measure.…”

Section: Overviewmentioning

confidence: 99%

Toward a Core Nutraceutical Program for Cancer Management

McCarty

Block

2006

Integr Cancer Ther

View full text Add to dashboard Cite

As previously suggested, it may be feasible to impede tumorevoked angiogenesis with a nutraceutical program composed of glycine, fish oil, epigallocatechin-3-gallate, selenium, and silymarin, complemented by a low-fat vegan diet, exercise training, and, if feasible, a salicylate and the drug tetrathiomolybdate. It is now proposed that the scope of this program be expanded to address additional common needs of cancer patients: blocking the process of metastasis; boosting the cytotoxic capacity of innate immune defenses (natural killer [NK] cells); preventing cachexia, thromboembolism, and tumor-induced osteolysis; and maintaining optimal micronutrient status. Modified citrus pectin, a galectin-3 antagonist, has impressive antimetastatic potential. Mushroom β-glucans and probiotic lactobacilli can amplify NK activity via stimulatory effects on macrophages. Selenium, β-carotene, and glutamine can also increase the number and/or cytotoxic activity of NK cells. Cachectic loss of muscle mass can be opposed by fish oil, glutamine, and β-hydroxy-β-methylbutyrate. Fish oil, policosanol, and vitamin D may have potential for control of osteolysis. High-dose aspirin or salicylates, by preventing NF-κB activation, can be expected to aid prevention of metastasis and cachexia while down-regulating osteolysis, but their impacts on innate immune defenses will not be entirely favorable. A nutritional insurance formula crafted for the special needs of cancer patients can be included in this regimen. To minimize patient inconvenience, this complex core nutraceutical program could be configured as an oil product, a powder, and a capsule product, with the nutritional insurance formula provided in tablets. It would be of interest to test this program in nude mouse xenograft models.

show abstract

Misoprostol Dosage in the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Gastric and Duodenal Ulcers: A Comparison of Three Regimens

Abstract: Misoprostol, 200 micrograms twice or three times daily, offers substantial protection against gastric and duodenal ulcers in patients receiving long-term NSAID therapy. These dosages were better tolerated than the currently approved regimen of 200 micrograms four times daily.

Cited by 162 publications

References 0 publications

A guideline for the treatment and prevention of nsaid-induced ulcers

A guideline for the treatment and prevention of nsaid-induced ulcers

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

Toward a Core Nutraceutical Program for Cancer Management

Contact Info

Product

Resources

About